ResearcherUniversity of BolognaActive in the last 2 years
Mirco Masi
Matched on ORCID iD 0000-0003-0919-5206; OpenAlex author ID A5055857436. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 3
- Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic A… Co-author DOI 10.1021/acsmedchemlett.5c00711↗
- Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. Co-author DOI 10.1038/s41420-025-02382-3↗
- Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthetic lethality in pancreatic cancer First author DOI 10.21203/rs.3.rs-4031427/v1↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Greta Bagnolini · 3 shared papers, 2024–2026 · strength 0.60
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Marinella Roberti · 3 shared papers, 2024–2026 · strength 0.60
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Stefania Girotto · 3 shared papers, 2024–2026 · strength 0.60
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Andrea Cavalli · 3 shared papers, 2024–2026 · strength 0.60
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Giovanni Ferrandi · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Naomi Walsh · 2 shared papers, 2024–2025 · strength 0.35
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Samuel Harry Myers · 2 shared papers, 2024–2025 · strength 0.35
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Shannon R. Nelson · 2 shared papers, 2024–2025 · strength 0.35
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.